

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on February 7, 2005

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1635
Patent Application
Docket No. USF-T150CX
Serial No. 09/955,174

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Jane J. Zara
Art Unit : 1635
Applicant : William G. Kerr
Serial No. : 09/955,174
Filed : September 19, 2001
Conf. No. : 9411
For : Control of NK Cell Function and Survival by Modulation of SHIP Activity

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed. However, the applicant has not submitted copies of the U.S. patent or published U.S. application cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
P.O. Box 142950
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of some references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/955,174	
			Filing Date	September 19, 2001	
			First Named Inventor	William G. Kerr	
			Art Unit	1635	
			Examiner Name	Jane J. Zara	
Sheet	1	of	2	Attorney Docket Number	USF-T150CX

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-6,703,215	03-09-2004	Erneux et al.	All
	U2	US-2004/0072298	04-15-2004	Sauvageau et al.	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Group Art Unit	1635
Examiner Name	Jane J. Zara
Attorney Docket Number	USF-T150CX

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AGRAWAL, S. "Antisense oligonucleotides: towards clinical trials" <i>TIBTECH</i> , 1996, 14:376-387.	
	R2	BRAASCH, D.A. and COREY, D.R. "Novel antisense and peptide nucleic acid strategies for controlling gene expression" <i>Biochemistry</i> , 2002, 41(14):4503-4510.	
	R3	GEWIRTZ, A.M. <i>et al.</i> "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise" <i>Proc. Natl. Acad. Sci. USA</i> , 1996, 93:3161-3163.	
	R4	HELGASON, C.D. <i>et al.</i> "Homeostasis and regeneration of the hematopoietic stem cell pool are altered in SHIP-deficient mice" <i>Blood</i> , 2003, 102:3541-3547.	
	R5	JEN, K-Y and GEWIRTZ, A.M. "Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies" <i>Stem Cells</i> , 2000, 18:307-319.	
	R6	LIU, L. <i>et al.</i> "The Src homology 2 (SH2) domain of SH2-containing inositol phosphatase (SHIP) is essential for tyrosine phosphorylation of SHIP, its association with Shc, and its induction of apoptosis" <i>J. Biol. Chem.</i> , 1997, 272:8983-8988.	
	R7	MOODY, J.L. <i>et al.</i> "Anemia, thrombocytopenia, leukocytosis, extramedullary hematopoiesis, and impaired progenitor function in Pten ^{-/-} SHIP ^{-/-} mice: a novel model of myelodysplasia" <i>Blood</i> , 2004, 103:4503-4510.	
	R8	OKADA, H. <i>et al.</i> "Cutting edge: Role of the inositol phosphatase SHIP in B cell receptor-induced Ca ²⁺ oscillatory response" <i>J. Immunol.</i> , 1998, 161:5192-5132.	
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.